Abstract
In a double-blind comparison of haloperidol decanoate and fluphenazine decanoate given 4-weekly for 60 weeks as maintenance therapy in 38 chronic schizophrenic in-patients, plasma haloperidol, fluphenazine and prolactin levels were measured at regular intervals by radioimmunoassay. After the first injection, the mean plasma haloperidol level was highest at week 1 and fell gradually towards week 4. Mean pre-dose haloperidol levels changed little after week 8. Results suggested an absorption half-life of 4 weeks, although, in three cases steady state was only achieved after 11 monthly injections. Steady state levels of both haloperidol and fluphenazine correlated highly with dose. In two subgroups observed at steady state, both drugs produced a biphasic pattern of plasma drug concentration between injections, a rapid rise on day 1 followed by stable elevated levels and a gradual return to pre-injection concentration by the end of week 4. In the fluphenazine subgroup there was a second peak on day 7 and a steeper decline, so that the mean area-under-curve in week 4 was 64% of that in week 1. Drug injections at steady state induced an increase in prolactin secretion in all of the fluphenazine sub-group and in half of those receiving haloperidol. Plasma prolactin changes resembled those for drug concentrations, but differences in times of peaks on day 1 resulted in weak correlations. Fluphenazine appeared more potent than haloperidol in provoking prolactin secretion.
Similar content being viewed by others
References
Altamura AC, Curry SH, Montgomery S, Wiles DH (1985) Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients. Psychopharmacology 87:30–33
Beumont PJV, Corker CS, Friesen HG, Kolakowska T, Mandelbrote BM, Marshall J, Murray MAF, Wiles DH (1974) The effects of phenothiazines on endocrine function. II. Effects in men and post-menopausal women. Br J Psychiatry 124:420–430
British National Formulary (1984) British Medical Association and the Pharmaceutical Society of Great Britain, London
Chalmers RJ, Bennie EH (1978) The effect of fluphenazine on basal prolactin concentrations. Psychol Med 8:483–486
Chang SS, Javaid JI, Dysken MW, Casper RC, Janicak PG, Davis JM (1985) Plasma levels of fluphenazine during fluphenazine decanoate treatment in schizophrenia. Psychopharmacology 87:55–58
Chouinard G, Annable L, Campbell W, Boisvert D, Bradwejn J (1984) A double-blind controlled trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Psychopharmacol Bull 20:108–109
Cookson JC, Kennedy NM, Gribbon D (1986) Weight gain and prolactin levels in patients on long-term antipsychotic medication: a double-blind comparative trial of haloperidol decanoate and fluphenazine decanoate. In: Silverstone T (ed) Depot antipsychotics in practice. Clinical Neuroscience Publishers, London, pp 41–51
Creese I, Lader S, Rosenberg B (1981) A radioreceptor assay for neuroleptic drugs. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry, neuroleptic and antidepressant research. Macmillan, London, pp 79–104
Curry SH, Whelpton R, Deschepper PJ, Vrancks S, Schiff AA (1978) Plasma fluphenazine concentrations after injections of long-acting esters. Lancet I:1217–1218
Curry SH, Whelpton R, Deschepper PJ, Vrancks S, Schiff AA (1979) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 7:325–331
Davis JM (1976) Comparative doses and costs of antipsychotic medication Arch Gen Psychiatry 33:858–861
Deberdt R, Elens P, Berghmans W, Heykants J, Woestenborghs R, Driesens F, Reyntjens A, Van Wijngaarden I (1980) Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Efficacy, dosage schedule and plasma levels. Acta Psychiatr Scand 62:356–363
De Cuyper H, Ballen J, Van Praag HM, Verstraeten D (1986) Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. Br J Psychiatry 148:560–566
Feighner JP, Robins E, Guze S, Woodruff RA, Winokur G, Munoz R (1972) Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 26:57–62
Forsman A, Öhman R (1976) Pharmacokinetic studies on haloperidol in man. Curr Ther Res 20:319–336
Goode DJ, Meltzer HY, Fang VF (1981) Daytime variation in serum prolactin levels in patients receiving oral and depot antipsychotic medication. Biol Psychiatry 16:653–662
Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, Hollister LE (1983) Clin Pharmacol Ther 33:477–484
Kissling W, Moller HJ, Walter K, Wittman B, Krueger R, Trenk D (1985) Double blind comparison of haloperidol decanoate and fluphenazine decanoate. Effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention. Pharmacopsychiatry 18:240–245
Kolakowska T, Braddock L, Wiles D, Franklin M, Gelder M (1981) Neuroendocrine tests during treatment with neuroleptic drugs I. Plasma prolactin response to haloperidol challenge. Br J Psychiatry 139:400–412
Langer G, Sachar EJ, Gruen PH, Halpern FS (1977) Human prolactin responses to neuroleptic drugs correlate with antispychotic potency. Nature 266:639–640
Marder SR, Hawes EM, Van Putten T, Hubbard JW, McKay G, Mintz J, May PRA, Midha KK (1986) Fluphenazine levels in patients receiving low and conventional dose of fluphenazine decanoate. Psychopharmacology 88:480–483
McKane JP, Robinson ADT, Wiles DH, McCreadie RG, Stirling GS (1987) Haloperidol decanoate -v- fluphenazine decanoate as maintenance therapy in chronic psychiatric in-patients. Br J Psychiatry 151:333–336
Naber D, Finkbeiner C, Fischer B, Zander KJ, Ackenheil M (1980) Effects of long-term neuroleptic treatment on prolactin and norepinephrine levels in serum of chronic schizophrenics: relations to psychopathology and extra-pyramidal symptoms. Neuropsychobiology 6:181–189
Nasrallah H, Rivera-Calimlim L, Rogol AD, Gillin JE, Wyatt RJ (1979) Fluphenazine decanoate and prolactin: plasma concentrations and clinical response. In: Merlis S, Gottschalk L (eds) Pharmacokinetics of psychoactive drugs: blood levels and clinical response. SP Medical and Scientific Books, New York London, pp 115–123
Nokin J, Vekemans M, L'Hermite M, Robyn C (1972) Circadian periodicity of serum prolactin concentration in man. Br Med J 3:561–562
Reyntjens AJM, Heykants JJP, Woestenborgs R, Gelders YG, Aerts TJL (1982) Pharmacokinetics of haloperidol decanoate. A two-year follow-up. Int Pharmacopsychiatry 17:238–246
Richards MS, Dato ACA, Zalaschi NM, Balbo EA, Canero EC (1982) Monthly haloperidol substitutes for daily neuroleptics in psychotic in-patients. Curr Ther Res 32:586–589
Rubin RT, Hays SE (1980) The prolactin secretory response to neuroleptic drugs: mechanisms, applications and limitations. Psychoneuroendocrinology 5:121–137
Sassin JF, Frantz AG, Weitzman ED, Kapen S (1972) Human prolactin: 24-hour pattern with increased release during sleep. Science 177:1205–1207
Suy E, Woestenborgs C, Heykants J (1982) Bioavailability and clinical effects of two different concentrations of haloperidol decanoate. Curr Ther Res 31:982–991
Wiles DH, Franklin M (1978) Radioimmunoassay for fluphenazine in human plasma. Br J Clin Pharmacol 5:265–268
Wiles DH, Gelder MG (1979) Plasma fluphenazine levels by radio-immunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate. Br J Clin Pharmacol 8:565–570
Wiles DH, Stump K, Franklin M, Fraser S (1981) Preliminary assessment of a calf caudate radioreceptor assay for the estimation of neuroleptic drugs in plasma: comparison with other techniques. In: Usdin E, Dahl SG, Gram LF, Lingaerde O (eds) Clinical pharmacology in psychiatry, neuroleptic and anti-depressant research. Macmillan, London
Wyatt RJ, Torgow JS (1976) A comparison of equivalent clinical potencies of neuroleptics as used to treat schizophrenia and affective disorders. J Psychiatr Res 13: 91–98
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wiles, D.H., McCreadie, R.G. & Whitehead, A. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia. Psychopharmacology 101, 274–281 (1990). https://doi.org/10.1007/BF02244140
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02244140